US Cancer/Tumor Profiling Market (2022-2027)
The US Cancer/Tumor Profiling Market was valued at $1175.3 Million in 2022 and projected to reach to $1425.1 Million by 2027, representing a compound annual growth rate of CAGR 3.9%. The US cancer/tumor profiling market is positioned for steady growth through 2027, driven by the integration of precision oncology into mainstream cancer care.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Cancer/Tumor Profiling Market Trends and Insights
- The US market is driven by increasing adoption of precision oncology, rising prevalence of cancer diagnoses, and growing investment in genomic testing infrastructure across US healthcare systems.
- Advanced molecular profiling technologies and personalized treatment approaches continue to reshape the US oncology landscape, with healthcare providers increasingly integrating tumor profiling into standard care protocols. The US cancer/tumor profiling market benefits from robust reimbursement frameworks, established regulatory pathways, and a mature healthcare ecosystem that supports innovation.
- US laboratories and diagnostic centers are expanding their profiling capabilities to meet growing demand for comprehensive genomic analysis.
- The market expansion reflects the US healthcare system's commitment to precision medicine and improved patient outcomes through data-driven treatment selection..
Key Market Statistics
- CAGR (2022-2027) CAGR 3.9%
- Market Size, 2022 ~USD 1175.3 Million
- Forecast, 2027 ~USD 1425.1 Million
- Country US
US Cancer/Tumor Profiling Market Overview
Market Size & Growth :
The US cancer/tumor profiling market reached $1,175.3 million in 2022 and is expected to grow to $1,425.1 million by 2027, with a CAGR of 3.9%, reflecting steady expansion in precision oncology adoption across American healthcare systems.
Precision Oncology Adoption :
Increasing adoption of precision medicine and genomic profiling in US oncology practices is driving market growth, as healthcare providers integrate molecular testing into standard cancer treatment protocols for improved patient outcomes.
Cancer Prevalence & Diagnosis :
Rising prevalence of cancer diagnoses in the US population combined with growing awareness of personalized treatment options is fueling demand for comprehensive tumor profiling services across major healthcare networks.
Genomic Infrastructure Investment :
Substantial investment in genomic testing infrastructure and laboratory capabilities across US healthcare systems is expanding access to advanced molecular profiling technologies and supporting market expansion.
US Cancer/Tumor Profiling Market Dynamics
- Healthcare providers are increasingly investing in genomic testing capabilities to enable personalized treatment strategies, supported by favorable reimbursement policies and growing clinical evidence demonstrating the value of molecular profiling in improving patient outcomes. Key growth drivers include rising cancer incidence rates, expanding insurance coverage for genomic tests, and technological advances in sequencing and analysis platforms.
- The market will benefit from continued consolidation among diagnostic laboratories, increased adoption of liquid biopsy technologies, and growing collaboration between academic medical centers and commercial testing providers across the US healthcare landscape..
Market Ecosystem
CANCER TUMOR PROFILING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Through Foundation Medicine and Roche Diagnostics, the company provides comprehensive genomic profiling (CGP) solutions using tissue and liquid biopsy-based testing to identify actionable biomarkers and support companion diagnostic applications for targeted therapies and immunotherapies. | Enables accurate patient stratification, improves therapy selection, supports biomarker-driven treatment decisions, and accelerates adoption of precision oncology workflows. |
 |
Provides next-generation sequencing (NGS) platforms and oncology-focused assays, including TruSight Oncology Comprehensive, to enable multi-gene tumor profiling and detection of clinically relevant biomarkers across solid tumors. | Supports comprehensive biomarker identification, improves laboratory testing scalability, enables decentralized genomic testing, and supports pharmaceutical companion diagnostic development. |
 |
Provides liquid biopsy-based tumor profiling solutions, including Guardant360 CDx and related genomic testing platforms, for detecting actionable genomic alterations, monitoring treatment response, and supporting therapy selection in advanced cancers. | Enables minimally invasive testing, facilitates repeat monitoring, identifies resistance mechanisms, and expands access to precision oncology testing for patients with limited tissue availability. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Key Takeaways
- The US cancer/tumor profiling market reached $1,175.3 million in 2022 with projected growth to $1,425.1 million by 2027.
- The US market is expanding at a 3.9% CAGR, driven by precision oncology adoption and genomic testing infrastructure investment.
- US healthcare providers are increasingly integrating tumor profiling into standard care protocols for improved treatment selection.
- The US market benefits from established reimbursement frameworks and regulatory pathways supporting innovation in molecular diagnostics.
Cancer/Tumor Profiling Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2022 |
| Fastest Growing Segment | NEXT-GENERATION SEQUENCING (Technology) |
| Forecast Period | 2022-2027 |
| Growth Rate | CAGR of 10.6% from 2022 to 2027 |
| Largest Segment | RESEARCH APPLICATIONS (Application) |
| Market Size Base Year (Billions) | ~USD 9.67 (2022) |
| Revenue Forecast (Billions) | ~USD 16 (2027) |
| Segments Covered | Technology, Cancer Type, Biomarker Type, Application, Type |
US Cancer/Tumor Profiling Market Report Segmentation
5 segment dimensions are covered across the global market.
By Technology
- Immunoassays
- In Situ Hybridization
- In-Situ Hybridization
- Mass Spectrometry
- Microarrays
- Next-Generation Sequencing
- Other Technologies
- Others Technologies
- Polymerase Chain Reaction
By Cancer Type
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Melanoma Cancer
- Other Cancers
- Prostate Cancer
By Biomarker Type
- Genetic Biomarkers
- Genomic Biomarkers
- Other Biomarkers
- Protein Biomarkers
By Application
- Clinical Applications
- Research Applications
By Type
- Biomarker Discovery
- Diagnostics
- Monitoring & Treatment
- Personalized Medicine
- Prognostics
- Screening
Target Audience
- Diagnostic Laboratory Operators : Need US market data to assess growth opportunities, plan capacity expansion, evaluate competitive positioning, and make informed decisions about genomic testing service offerings and technology investments.
- Pharmaceutical & Biotech Companies : Require market intelligence on US tumor profiling adoption to develop companion diagnostics, identify patient populations for clinical trials, and align oncology drug development strategies with precision medicine trends.
- Healthcare System Executives : Need market insights to justify investments in genomic testing infrastructure, evaluate vendor partnerships, benchmark against peer institutions, and develop precision oncology programs across US hospital networks.
- Medical Device & IVD Manufacturers : Require US-specific market data to guide product development roadmaps, identify distribution channels, assess reimbursement opportunities, and position sequencing and profiling technologies in the American market.
- Healthcare Investors & Consultants : Need comprehensive US market analysis to evaluate investment opportunities in cancer diagnostics, support due diligence for M&A transactions, and provide strategic guidance to healthcare organizations and diagnostic companies.
Reasons to Buy this Report
- Market Size & Valuation Data : Access precise US market valuation figures ($1,175.3M in 2022) and 5-year forecasts ($1,425.1M by 2027) to benchmark competitive positioning and identify revenue opportunities in the American cancer profiling segment.
- Growth Trajectory Analysis : Understand the 3.9% CAGR trajectory specific to the US market, enabling strategic planning for product launches, facility expansion, and market entry timing aligned with regional growth patterns.
- US-Specific Market Drivers : Gain insights into US-specific growth catalysts including precision oncology adoption rates, cancer prevalence trends, reimbursement landscape, and healthcare infrastructure investments driving market expansion.
- Competitive Landscape Intelligence : Identify market opportunities and competitive gaps within the US cancer profiling sector to inform product development, partnership strategies, and go-to-market approaches for diagnostic and pharmaceutical companies.
- Investment & Strategic Planning : Support capital allocation decisions, M&A strategies, and business development initiatives with comprehensive US market data, enabling informed decisions on laboratory expansion, technology acquisition, and market consolidation opportunities.
Frequently asked questions
What is the current size of the US cancer/tumor profiling market?
The US cancer/tumor profiling market was valued at $1,175.3 million in 2022 and is expected to reach $1,425.1 million by 2027.
What is the growth rate of the US cancer/tumor profiling market?
The US cancer/tumor profiling market is growing at a compound annual growth rate (CAGR) of 3.9% from 2022 to 2027.
What factors are driving growth in the US cancer/tumor profiling market?
Key drivers include increasing adoption of precision oncology, rising cancer prevalence, growing investment in genomic testing infrastructure, and robust US reimbursement frameworks supporting molecular diagnostics.
How is the US cancer/tumor profiling market structured?
The US market comprises diagnostic laboratories, hospital-based testing centers, and specialized genomic profiling providers offering comprehensive molecular analysis for treatment selection.
What role does precision medicine play in the US cancer/tumor profiling market?
Precision medicine is central to the US market, with healthcare providers increasingly using tumor profiling data to guide personalized treatment decisions and improve patient outcomes.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the cancer tumor profiling market. Exhaustive secondary research was conducted to collect information on the market, its peer markets, and the broader precision-oncology ecosystem. The findings, assumptions, and market sizing estimates were then validated through primary research with participants across the value chain. Both top-down and bottom-up approaches were used to estimate the complete market. Following this, data triangulation was applied to finalize the market size and the values of individual segments and subsegments.
Secondary Research
Secondary research was used to identify and gather information for this extensive technical, market-oriented, and commercial study. Public-sector sources included the US Food and Drug Administration (FDA), National Institutes of Health (NIH), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), International Agency for Research on Cancer (IARC), Global Cancer Observatory (GLOBOCAN), European Medicines Agency (EMA), European Commission, and relevant national health ministries and cancer registries.
Company and industry sources included annual reports, SEC and other regulatory filings, investor presentations, earnings releases, product catalogs, regulatory databases, company websites, scientific publications, clinical trial registries, peer-reviewed journals, and publications from pathology, genomics, oncology, and laboratory medicine associations. These sources were used to identify major participants, product and service portfolios, regulatory approvals, installed sequencing and pathology capabilities, test volumes, oncology revenue exposure, partnerships, clinical-trial activity, regional presence, technology adoption, and market developments.
Secondary data were analyzed to estimate the overall cancer tumor profiling market and to construct preliminary splits by product and service, technology, sample type, application, cancer type, end user, and region. The resulting estimates were subsequently validated and refined through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including executives of diagnostics and life-science companies, laboratory directors, molecular pathologists, oncologists, sequencing specialists, product managers, business-development leaders, clinical-trial professionals, and subject-matter experts. Interviews were conducted across both the supply and demand sides to validate market definitions, adoption levels, average selling prices, test volumes, technology mix, regional variation, end-user behavior, growth assumptions, and competitive positioning:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global cancer tumor profiling market was estimated through multiple complementary approaches. A detailed market-engineering model was used to estimate and validate the overall market and each segment. The process combined company-level revenue analysis, product and service mapping, test-volume assessment, installed-base evaluation, average selling price analysis, end-user demand estimation, and regional adoption patterns. The research methodology used to estimate the market size includes the following:
Cancer Tumor Profiling Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market through the market-size estimation process, the total market was split into the defined segments and subsegments. To complete the market-engineering process and arrive at the final statistics, data triangulation was employed. The process examined factors and trends from both the demand and supply sides and reconciled company revenues, test volumes, installed systems, consumable pull-through, service revenue, technology adoption, cancer incidence, biomarker-testing patterns, and regional market conditions.
The final estimates were checked for consistency across all dimensions. For example, the product and service totals were reconciled with technology, sample type, application, cancer type, end user, and regional totals. Company-share estimates were also compared with the independently derived global market size to ensure that no major revenue pools were omitted or double-counted.
Market Definition
Cancer tumor profiling refers to the analysis of molecular, genomic, proteomic, and histopathologic characteristics of tumor material to support cancer diagnosis and molecular characterization, prognostic or risk assessment, treatment selection, companion diagnostic use, treatment-response and resistance monitoring, residual disease assessment, post-treatment surveillance, recurrence detection, biomarker discovery, and oncology drug development.
The market includes instruments and systems; assays, kits, reagents, and consumables; clinical tumor profiling testing services; and biopharmaceutical, clinical-trial, and companion diagnostic services. It covers next-generation sequencing, PCR-based technologies, immunohistochemistry, in situ hybridization, and other tumor profiling technologies applied to tissue, whole blood and plasma, bone marrow, and other relevant samples across solid tumors and hematologic malignancies.
The market excludes unrelated general laboratory testing, non-oncology molecular diagnostics, routine pathology procedures that do not contribute to tumor characterization, and hereditary or germline testing performed outside a cancer tumor profiling workflow.
Key Stakeholders
- Manufacturers and distributors of cancer tumor profiling instruments and systems
- Assay, kit, reagent, antibody, probe, and consumable suppliers
- Next-generation sequencing, PCR, IHC, and ISH technology providers
- Clinical tumor profiling and liquid-biopsy testing laboratories
- Hospitals, dedicated cancer centers, and oncology clinics
- Independent and specialty reference laboratories
- Pharmaceutical and biotechnology companies
- Contract research organizations and central laboratories
- Companion diagnostic developers and service providers
- Research institutes and academic medical center laboratories
- Regulatory agencies, reimbursement bodies, and cancer registries
- Market research and consulting firms
- Private equity firms, venture capitalists, and other investors.
Report Objectives
- To define, describe, segment, and forecast the global cancer tumor profiling market by offering, technology, sample type, application, cancer type, end user, and region
- To provide detailed information regarding the major factors influencing market growth, including drivers, restraints, opportunities, and challenges
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall cancer tumor profiling market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to six regions: North America(US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC and the Rest of Middle East], and Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, collaborations, expansions, and other developments
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
-
Further breakdown of the Rest of Europe cancer/tumor profiling market, by country
-
Further breakdown of the Rest of Asia Pacific cancer/tumor profiling market, by country
Company Information
-
Detailed analysis and profiling of additional market players (up to five)
-
Further breakup of additional Asia Pacific countries by offering, deployment mode, enterprise size, application, and vertical
-
Further breakup of additional Middle Eastern & African countries by offering, deployment mode, enterprise size, application, and vertical
Segment Analysis
- Cross-segment analysis
Get the Full Cancer/Tumor Profiling Market Report
Full forecast, segment splits, and company analysis for all Cancer/Tumor Profiling Market.
- Canada Cancer/Tumor Profiling Market
- France Cancer/Tumor Profiling Market
- Germany Cancer/Tumor Profiling Market
- Italy Cancer/Tumor Profiling Market
- Spain Cancer/Tumor Profiling Market
- UK Cancer/Tumor Profiling Market
- China Cancer/Tumor Profiling Market
- India Cancer/Tumor Profiling Market
- Japan Cancer/Tumor Profiling Market
- Rest Of Europe Cancer/Tumor Profiling Market
- Roapac Cancer/Tumor Profiling Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
